Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases. 2011

Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
Department of Pathology, School of Medicine Nanjing University/Nanjing Jinling Hospital, Nanjing, P.R. China.

Lipid-rich carcinoma of the breast is a rare variant of breast cancer, accounted for <1% of all breast malignant tumors. We retrospectively analyzed the clinicopathologic characteristics of lipid-rich carcinomas of the breast. A panel of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2 (HER-2), cytokeratin (CK) 5/6, CK14, and P63 was prepared for detection of lipid-rich carcinoma. Fluorescence in situ hybridization and electron microscope assays were performed for detecting HER-2 gene amplification and ultrastructure. Survival analysis were carried out using Kaplan-Meier and Cox regression methods. Receiver operating characteristic test was also performed. Estrogen receptor, CK5/6, CK14, and P63 were negative. Progesterone receptor (1/17) and HER-2 (17/17) were positive. HER-2 gene amplification was detected in all included cases (ratio values >2.2). Ultrastructure showed fat droplet and electron-dense material in the cytoplasm. Statistical differences were detected among survival and age (P = .033), histologic grade (P = .004), lymph node involvement (P = .001), and HER-2 expression (P = .002), respectively, using Kaplan-Meier methods. Statistical differences were also detected (P = .017) using Cox regression methods. Receiver operating characteristic test displayed significant statistical differences; the prognosis had a correlation between HER-2 expression "+" and HER-2 expression "++" (P = .004). Lipid-rich carcinoma of the breast was an HER-2 overexpressing subtype of the breast carcinoma. Survival of lipid-rich carcinoma might be associated with age, histologic grade, lymph node involvement, and HER-2. The HER-2 expression, however, might play an important role in predicting the prognosis of lipid-rich carcinoma of the breast.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene

Related Publications

Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
March 1974, Cancer,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
July 2017, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
June 2017, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
August 1995, The American journal of surgical pathology,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
January 2008, Tumori,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
December 2017, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
October 2017, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
November 1998, Pathology international,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
March 2009, The American journal of surgical pathology,
Bing Guan, and Hai Wang, and Shougen Cao, and Qiu Rao, and Yan Wang, and Yun Zhu, and Qunli Shi, and Honglin Yin, and Xuan Wang, and Xiaojun Zhou
January 2002, Magyar onkologia,
Copied contents to your clipboard!